8th IAS Conference on HIV Pathogenesis, Treatment and Prevention*

July 19-22, 2015; Vancouver, Canada
CCO is the official provider of online scientific analysis for the 2015 International AIDS Society meeting, through Capsule Summaries, downloadable slides, and CME-certified faculty analysis of key studies.

Prevention, HCV Coinfection, and Other Highlights

Capsules

In this randomized, open-label trial, the number of externally verified TB diagnoses was higher among patients who received empiric TB treatment vs those who received only isoniazid preventive therapy at ART initiation.

Released: July 22, 2015

During a 10-year period, immediate ART was associated with a 93% reduction in the risk of HIV transmission between serodiscordant couples when compared with initiating ART after CD4+ cell counts dropped to 250.

Released: July 22, 2015

Suboptimal adherence to required doses reduced with daily, time-driven, and event-driven dosing strategies, suggesting additional interventions needed to optimize PrEP adherence in this population.

Released: July 22, 2015

Although daily PrEP was associated with higher adherence and drug concentrations than were time-driven and event-driven PrEP, time-driven PrEP was associated with high drug coverage and required fewer doses.

Released: July 23, 2015

In this Canadian retrospective analysis, no cases of mother-to-child HIV transmission occurred among 18 women who received raltegravir during pregnancy because of concerns regarding risk of vertical transmission (drug resistance, detectable HIV-1 RNA, late ART initiation).

Released: July 23, 2015

Higher SVR12 rates were observed regardless of previous HCV treatment experience or presence of cirrhosis; lower response rates observed in black vs nonblack patients.

Released: July 24, 2015

SVR12 rates with grazoprevir/elbasvir in HCV/HIV-coinfected patients comparable to those of HCV-monoinfected patients with no impact on HIV disease or serious treatment-related adverse events.

Released: July 26, 2015

Adherence was relatively high but varies according to study site and participant race; HIV-1 incidence rate was low at 0.43/100 person-years.

Released: July 23, 2015

Black MSM had the lowest adherence levels across the study and a sharp drop off in adherence occurred among all participants between Week 12 and Week 24, corresponding to a reduced frequency of study visits beginning at Week 12.

Released: July 28, 2015
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Produced in collaboration with
Educational grant provided by:
Bristol-Myers Squibb
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?